Grundinformationen
- Standard-SMILES
Cc1ccc(NS(=O)(=O)c2cccc(C#N)c2)c2[nH]cc(C#N)c12- InChIKey
LWGUASZLXHYWIV-UHFFFAOYSA-N- Summenformel
- C17H12N4O2S
- Durchschnittliche Molmasse
- 336,4 g/mol
- Monoisotopische Masse
- 336,06809662
Überblick
E7820 has been investigated for the treatment of Colon Cancer and Rectal Cancer.
Namen und Bezeichner
- Bevorzugter Name
- E 7820
- IUPAC
- 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide
- Englischer Name
- E-7820
- Summenformel
- C17H12N4O2S
- Molmasse
- 336.37
Namen und Synonyme
Weitere Namen anzeigen
Datenbank-Bezeichner
- CAS
289483-69-8- PubChem CID
- 196970
- DTXSID
DTXSID20183142- ChEMBL
CHEMBL4297376- UNII
- TVH5K7949N
- Nikkaji
- J1.844.794K
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 2,4
- Polarare Oberfläche (TPSA)
- 118 Ų
- H-Brücken-Donoren
- 2
- H-Brücken-Akzeptoren
- 5
- Frei drehbare Bindungen
- 3
- Schwere Atome
- 24
- Formalladung
- 0
- Komplexität
- 668
Experimentelle und physikochemische Eigenschaften
Physikochemische Eigenschaften
- Siedepunkt
- 626.2 · 626.2±65.0 °C(Predicted)
- Dichte
- 1.48 · 1.48±0.1 g/cm3(Predicted)
- storage temp.
- -20 °C · Store at -20°C
- Löslichkeit
- 67 · DMSO:67.0(Max Conc. mg/mL);199.19(Max Conc. mM)
- Aggregatzustand
- A crystalline solid
- pka
- 8.17 · 8.17±0.30(Predicted)
- Farbe
- Light yellow to light brown
- InChI
- InChI=1S/C17H12N4O2S/c1-11-5-6-15(17-16(11)13(9-19)10-20-17)21-24(22,23)14-4-2-3-12(7-14)8-18/h2-7,10,20-21H,1H3
- InChIKey
- LWGUASZLXHYWIV-UHFFFAOYSA-N
- SMILES
- C1(S(NC2C3=C(C(C)=CC=2)C(C#N)=CN3)(=O)=O)=CC=CC(C#N)=C1
Sicherheit und Regulatorisches
Sicherheitsdaten
- wgk
- WGK 3
- Speicherklasse
- 11 - Combustible Solids
Chemie und Industrie
Anwendungen
BeschreibungE7820 is a sulfonamide derivative and an angiogenesis inhibitor that inhibits bFGF- and VEGF-stimulated human umbilical vein endothelial cell (HUVEC) proliferation (IC50s = 0.1 and 0.081 μg/ml, respectively). It inhibits bFGF- and VEGF-stimulated tube formation of HUVECs in a concentration-dependent manner (IC50s = 0.2 and 0.24 μg/ml, respectively). E7820 selectively decreases the surface expression and mRNA levels of integrin α2 over CD31 and VE-cadherin in HUVECs. In vivo, E7820 (200 and 400 mg/kg) reduces tumor growth and inhibits angiogenesis in a WiDr colorectal cancer mouse xenograft model. It also reduces tumor weight in a panel of seven human colon, breast, pancreas, and kidney cancer mouse xenograft models, completely inhibits tumor growth in KP-1 pancreatic and LoVo colon cancer mouse xenograft models, and inhibits tumor growth in KP-1 and COLO 320DM mouse orthotopic transplantation models.
Anbieter50 Anbieter
Zugehörige Reaktionen
Verknüpfte Notizen
Wird geladen…